Tags

Type your tag names separated by a space and hit enter

Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study.
J Clin Pharm Ther. 2017 Feb; 42(1):44-50.JC

Abstract

WHAT IS KNOWN AND OBJECTIVE

Current treatments for depressive disorders are far from optimum. This study was planned to evaluate possible antidepressant effects and safety of memantine, a selective N-methyl-d-aspartate receptor antagonist, in humans.

METHODS

Sixty-six outpatients with the diagnosis of moderate-to-severe major depressive disorder, based on DSM-V diagnostic criteria, were recruited to participate in a parallel, randomized, controlled trial. Sixty-two participants completed 6 weeks of treatment with either memantine (20 mg/day) plus sertraline (200 mg/day) or placebo plus sertraline (200 mg/day). Patients were evaluated using the Hamilton Depression Rating Scale (HDRS) at baseline and at weeks 2, 4 and 6. Comparison of treatment efficacy in improving depressive symptoms between the two groups was the principal outcome measure.

RESULTS AND DISCUSSION

A repeated-measures analysis demonstrated significant time × treatment interaction on HDRS score [F (2·09, 125·67) = 5·09, P = 0·007]. Significantly greater improvement was seen at all three follow-up sessions as well as significantly greater response rates at weeks 4 and 6 (P = 0·018 and P < 0·001, respectively) in the memantine group. Significantly more early improvers and more rapid response to treatment were observed in the memantine group (P = 0·001 and P < 0·001, respectively). A significant reduction was observed in HDRS score from baseline to the study endpoint in both memantine (P < 0·001, Cohen's d = 12·71) and placebo groups (P < 0·001, Cohen's d = 5·13). No serious adverse event occurred. No significantly greater remission rate was seen in the adjunctive memantine therapy.

WHAT IS NEW AND CONCLUSION

A 6-week course of treatment with memantine as adjunct to sertraline showed a favourable safety and efficacy profile in patients with major depressive disorder. Nonetheless, larger controlled studies of longer duration are necessary to assess long-term safety, efficacy and optimal dosing.

Authors+Show Affiliations

Department of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.Department of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.Department of Neuroscience, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27809351

Citation

Amidfar, M, et al. "Effect of Memantine Combination Therapy On Symptoms in Patients With Moderate-to-severe Depressive Disorder: Randomized, Double-blind, Placebo-controlled Study." Journal of Clinical Pharmacy and Therapeutics, vol. 42, no. 1, 2017, pp. 44-50.
Amidfar M, Khiabany M, Kohi A, et al. Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. J Clin Pharm Ther. 2017;42(1):44-50.
Amidfar, M., Khiabany, M., Kohi, A., Salardini, E., Arbabi, M., Roohi Azizi, M., Zarrindast, M. R., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S. (2017). Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. Journal of Clinical Pharmacy and Therapeutics, 42(1), 44-50. https://doi.org/10.1111/jcpt.12469
Amidfar M, et al. Effect of Memantine Combination Therapy On Symptoms in Patients With Moderate-to-severe Depressive Disorder: Randomized, Double-blind, Placebo-controlled Study. J Clin Pharm Ther. 2017;42(1):44-50. PubMed PMID: 27809351.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. AU - Amidfar,M, AU - Khiabany,M, AU - Kohi,A, AU - Salardini,E, AU - Arbabi,M, AU - Roohi Azizi,M, AU - Zarrindast,M-R, AU - Mohammadinejad,P, AU - Zeinoddini,A, AU - Akhondzadeh,S, Y1 - 2016/11/03/ PY - 2016/05/26/received PY - 2016/09/26/accepted PY - 2016/11/4/pubmed PY - 2017/5/18/medline PY - 2016/11/4/entrez KW - clinical trial KW - glutamate KW - major depression disorder KW - memantine SP - 44 EP - 50 JF - Journal of clinical pharmacy and therapeutics JO - J Clin Pharm Ther VL - 42 IS - 1 N2 - WHAT IS KNOWN AND OBJECTIVE: Current treatments for depressive disorders are far from optimum. This study was planned to evaluate possible antidepressant effects and safety of memantine, a selective N-methyl-d-aspartate receptor antagonist, in humans. METHODS: Sixty-six outpatients with the diagnosis of moderate-to-severe major depressive disorder, based on DSM-V diagnostic criteria, were recruited to participate in a parallel, randomized, controlled trial. Sixty-two participants completed 6 weeks of treatment with either memantine (20 mg/day) plus sertraline (200 mg/day) or placebo plus sertraline (200 mg/day). Patients were evaluated using the Hamilton Depression Rating Scale (HDRS) at baseline and at weeks 2, 4 and 6. Comparison of treatment efficacy in improving depressive symptoms between the two groups was the principal outcome measure. RESULTS AND DISCUSSION: A repeated-measures analysis demonstrated significant time × treatment interaction on HDRS score [F (2·09, 125·67) = 5·09, P = 0·007]. Significantly greater improvement was seen at all three follow-up sessions as well as significantly greater response rates at weeks 4 and 6 (P = 0·018 and P < 0·001, respectively) in the memantine group. Significantly more early improvers and more rapid response to treatment were observed in the memantine group (P = 0·001 and P < 0·001, respectively). A significant reduction was observed in HDRS score from baseline to the study endpoint in both memantine (P < 0·001, Cohen's d = 12·71) and placebo groups (P < 0·001, Cohen's d = 5·13). No serious adverse event occurred. No significantly greater remission rate was seen in the adjunctive memantine therapy. WHAT IS NEW AND CONCLUSION: A 6-week course of treatment with memantine as adjunct to sertraline showed a favourable safety and efficacy profile in patients with major depressive disorder. Nonetheless, larger controlled studies of longer duration are necessary to assess long-term safety, efficacy and optimal dosing. SN - 1365-2710 UR - https://www.unboundmedicine.com/medline/citation/27809351/Effect_of_memantine_combination_therapy_on_symptoms_in_patients_with_moderate_to_severe_depressive_disorder:_randomized_double_blind_placebo_controlled_study_ L2 - https://doi.org/10.1111/jcpt.12469 DB - PRIME DP - Unbound Medicine ER -